EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Obesity Paradox in Cancer: A Complex Interplay Between Risk and Therapeutic Outcomes

Tong Chen, Wenjia Zhai, Jiaao Song, Wenqiang Liu, Zhenjie Wu, Fu Yang, Linhui Wang iD

MedComm · 2025-12 · 6 (12)

DOI: 10.1002/mco2.70494 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 18.11.2025. Verfasst von Tong Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Shanghai Changhai Hospital, Naval Medical University Shanghai China. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 214 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity is a recognized risk factor for cancer development and progression. Paradoxically, growing clinical evidence across several cancer types indicates that elevated body mass index (BMI) or specific body composition characteristics—such as increased visceral fat or preserved skeletal muscle—may be associated with moderately improved overall survival in patients undergoing immune checkpoint inhibitor (ICI) therapy. This seemingly contradictory phenomenon is often described as the “obesity paradox.” In this review, we delineate the etiological versus therapeutic implications of obesity, synthesizing data from non‐small cell lung cancer, renal cell carcinoma, melanoma, and hepatocellular carcinoma. Proposed explanations include low‐grade inflammation with signal transducer and activator of transcription 3‐mediated programmed death‐1 upregulation, insulin/insulin‐like growth factor‐1 signaling, adipokine imbalance, stromal fibrosis and hypoxia, and metabolic reprogramming that may alter T‐cell function and tumor immunogenicity. Nonbiological factors—including dosing strategies, sarcopenia, and sex‐specific differences—are also examined. We advocate for future research employing comprehensive body composition assessments, standardized pharmacokinetic/pharmacodynamic analyses, and consideration of sex and metabolic health. Clarifying the temporal and mechanistic basis of the obesity–ICI benefit relationship will inform the optimization of cancer immunotherapy.

Schlagwörter

Stichwörter der Autor:innen

body mass indeximmune checkpoint inhibitorsmetabolic dysregulationobesity paradoxtumor microenvironment

Autor:innen und Institutionen

  • Department of Urology Shanghai Changhai Hospital, Naval Medical University Shanghai China.
  • Department of Medical Genetics Naval Medical University Shanghai China.
  • Shanghai Key Laboratory of Medical Bioprotection Shanghai China.
  • Key Laboratory of Biological Defense Ministry of Education Shanghai China.

ORCID-Profile: Linhui Wang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Chen, T., Zhai, W., Song, J., Liu, W., Wu, Z., Yang, F., & Wang, L. (2025). Obesity Paradox in Cancer: A Complex Interplay Between Risk and Therapeutic Outcomes. MedComm, 6(12). https://doi.org/10.1002/mco2.70494

Vancouver

Chen T, Zhai W, Song J, Liu W, Wu Z, Yang F, et al. Obesity Paradox in Cancer: A Complex Interplay Between Risk and Therapeutic Outcomes. MedComm. 2025;6(12). doi:10.1002/mco2.70494

BibTeX
@article{Chen2025,
  author = {Chen, Tong and Zhai, Wenjia and Song, Jiaao and Liu, Wenqiang and Wu, Zhenjie and Yang, Fu and Wang, Linhui},
  title = {Obesity Paradox in Cancer: A Complex Interplay Between Risk and Therapeutic Outcomes},
  journal = {MedComm},
  year = {2025},
  volume = {6},
  number = {12},
  doi = {10.1002/mco2.70494}
}
Kostenlos starten →